Company · Healthtech & Bio

Flomics

flomics.com ↗ ·Barcelona ·Seed

Flomics is a Barcelona-based biotech company founded in 2018 that develops RNA-based liquid biopsy diagnostics, combining next-generation sequencing with machine learning to analyze circulating cell-free RNA (cfRNA) in blood. Its flagship product is a multicancer early-detection blood test targeting colorectal, lung, breast, prostate and pancreatic cancers, developed with clinical partners including Hospital Clínic Barcelona, Bern University Hospital and others. Founded by researchers/entrepreneurs from the Centre for Genomic Regulation (CRG) and Universitat Pompeu Fabra (UPF); has raised seed funding across multiple rounds (2022, 2024).

Founded

2018

Founders

News

Rounds

Investors

SectorsBiotechnology, Diagnostics, Liquid Biopsy, Genomics, Precision Medicine Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Profile updated 30 Jul 2026

Founders

André Guedes

COO & Co-founder

Esther Lizano

Chief Scientific Officer & Co-founder

João Curado

CEO & Co-founder

Luís Korrodi

Chief Business Officer & Co-founder

Global models 5

GRAIL

United States · grail.com ↗

Develops a multi-cancer early detection blood test (Galleri) using cell-free nucleic acid sequencing and machine learning, the closest large-scale analog to Flomics' cfRNA multicancer screening approach.

$2.0B+Comparable

Freenome

United States · www.freenome.com ↗

Uses blood-based multiomics (including cell-free RNA and proteins) plus machine learning for early cancer detection, directly mirroring Flomics' cfRNA plus ML diagnostic model.

$1.7BComparable

Guardant Health

United States · guardanthealth.com ↗

Liquid biopsy company using blood-based genomic analysis for cancer detection and monitoring, same core NGS-based liquid biopsy category as Flomics.

$550M (pre-IPO VC)Comparable

Thrive Earlier Detection

United States

Developed a multi-cancer blood test (CancerSEEK) combining genomic and protein biomarkers, acquired by Exact Sciences for $2.15B, a close model match to Flomics' multicancer blood test.

$257MComparable

DELFI Diagnostics

United States · delfidiagnostics.com ↗

Uses cell-free DNA fragmentation patterns and machine learning from a simple blood draw for early cancer detection, closely paralleling Flomics' cfRNA fragmentomics-plus-ML approach.

$300MComparable